Abstract
Atrial fibrillation (AF) increases risk of stroke fivefold. This is mainly due to cardioembolism of left atrial appendage thrombus to the cerebral circulation. Currently, the principal means of stroke prophylaxis is anticoagulation using warfarin, an oral vitamin K antagonist. However, owing to the risk of hemorrhage associated with warfarin, there is considerable interest in alternative means of stroke prophylaxis. This article summarizes the evidence that warfarin and recently developed novel oral anticoagulants (e.g., dabigatran, rivaroxaban, apixaban and tecarfarin) are effective for reducing stroke risk in AF patients. We also review the impact of newer approaches such as surgical and percutaneous left atrial appendage closure and AF-rhythm control strategies in reducing stroke risk.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
